Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
暂无分享,去创建一个
M. Konopleva | Z. Estrov | M. Andreeff | K. Bhalla | H. Kantarjian | G. Garcia-Manero | J. Cortes | T. Kadia | F. Ravandi | Koichi Takahashi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | S. Pierce | S. Kornblau | N. Pemmaraju | N. Short | Xuemei Wang | K. Sasaki | K. Naqvi | G. Issa | G. Bravo | Rashmi Malla